Objective: The aim of this study was to evaluate the demographic characteristics of patients with bilateral bisphosphonate-related low-energy femoral shaft fractures. Methods: The clinical registry was reviewed for patients with bisphosphonate-related low-energy fractures localized at femoral shaft between January 2008 and January 2012. Patients with a diagnosis of postmenopausal osteoporosis, bisphosphonate usage of at least 5 years and prodromal pain prior to fracture were included the study. Results: Five women met the inclusion criteria. All patients had bilateral low-energy sequential femoral shaft fractures. Fracture patterns were similar and atypical (transverse-short oblique fractures with lateral cortical thickening). Mean period of bisphosphonate treatment was 8.6 years. Mean patient age was 76.2 years. Union time of three patients was between 20 and 28 weeks. The remaining two fractures were revised for delayed union or nonunion. Conclusion: Long-term (over 5 years) use of bisphosphonates may cause insufficiency fractures due to increased fragility and brittleness which have a close relationship with depressed bone remodeling. While there is still no causal relationship between bisphosphonates and atypical, low-energy femoral shaft fractures, we have some concerns about the optimal usage time and long-term safety of bisphosphonate drugs.
Osteoporosis is a skeletal disease in which a low-density and micro-architectural defects in bone tissue increase susceptibility to fractures. [1] Currently it is estimated that more than 10 million patients have been diagnosed with osteoporosis in the US alone. [2] Considering a lifetime fracture risk of 40% for white females, these cases represent an approximately 9 million new osteoporotic fractures per annum. [3] Prevention of further bone resorption and fractures is the backbone of treatment. Following current evidence-based guidelines, bisphosphonates are often first considered for the treatment of osteoporosis. [4] This class of medication may account more than 80% of total prescriptions given for osteoporosis in some countries and their efficiency in treatment of postmenopausal osteoporosis was reported to reduce vertebral fractures by nearly 50% and hip fractures by 20 to 50%. [5] Bisphosphonates were shown to be well tolerated and safe in large-scale clinical trials. [6] Several rare and potentially serious adverse events have been reported to be associated with long-term bisphosphonate use from post-marketing reports and epidemioBilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy logical studies. These adverse events include dyspepsia, nausea, muscular pain, osteonecrosis of the jaw (ONJ), and atrial fibrillation. [7] In recent years, however, there have been increasing numbers of cases or case series about atypical subtrochanteric/femoral shaft fractures related to bisphosphonate treatment. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The aim of this study was to evaluate the demographic characteristics of patients with bilateral bisphosphonate-related low-energy femoral shaft fractures.
Patients and methods
In this retrospective observational study, the clinical registry of GATA Haydarpafla Training Hospital (Istanbul, Turkey) was reviewed for patients with femoral fractures between January 2008 and January 2012. Patients with a diagnosis of low-energy fractures at the femoral shaft were sorted out and along with the radiological appearance of these fractures, patients' demographics were recorded. Fractures occurring from a fall from standing height without any significant trauma were assessed as 'low-energy fractures'. Patients with a diagnosis of osteoporosis using bisphosphonate drugs for a minimum of 5 years and who had prodromal pain prior to fracture were included in this study. Included patients' fractures were labeled 'bisphosphonate-related low-energy fracture'. Local ethical committee approval was obtained.
Results
Fifty-two patients had femoral shaft fractures. Patient histories were reviewed for low-energy fractures and 
Discussion
Osteoporosis is a common health problem in the elderly population. Increased risk of fracture can result in disability, morbidity, decreased life quality, higher costs, and mortality. In postmenopausal osteoporotic patients, bisphosphonates have been shown to decrease the risk of vertebral and femoral neck fractures. [20] [21] [22] [23] Bisphosphonates are potent inhibitors of bone resorp- Fig. 3 . This impending fracture localized at the right femur diaphysis was also treated with interlocked intramedullary nailing. Left (22) Left (26) Left (26) (after revision surgery) (impending fracture) (after revision surgery)
Left (27) Left ( tion that inhibit osteoclast function and induce osteoclast apoptosis. [13, 24] Alendronate was approved by the FDA in 1995 for the treatment of osteoporosis. The pathophysiology of bisphosphonate associated fractures is thought to be associated with the inhibition of bone turnover and repair of microscopic trauma. In recent decades, human biopsy and experimental animal studies have reported suppressed bone turnover with bisphosphonate use. [17, [25] [26] [27] [28] As a result, a cycle of defective repair and continual micro-trauma compounded over time gradually weakens and creates more mineralized and brittle bones, an architectural conduit for transverse or insufficiency fractures. [13, [29] [30] [31] It has been advocated that some osteoclastic activity is necessary to repair microdamage and continuity of remodelization. [17, 32] In a recent study, Bala et al. reported that long-term (6 to 10 years) alendronate use compromises the micromechanical properties of bone and problems were related with lower crystallinity, associated with elastic modulus and contact hardness. [33] Our cases also had a minimum of 5 years of alendronate usage (range: 5 to 14 years). Extended alendronate use may diminish mechanical properties of bone and may result in more brittle bone which in turn can result in insufficiency fractures. In a detailed review, Ott [34] demonstrated the mechanism of action of bisphosphonates. First, the author emphasized the common misunderstanding that 'bisphosphonates build bone'. Second, she cited an article on fluoride treatment for osteoporosis treatment and underlined that despite increased bone density, the bone becomes more fragile. This can be example for this clinical picture of what bisphosphonate drugs do. It was also reported that overall fracture risk is similar in patients with more than 5 years of bisphosphonate use and individuals who stopped therapy.
Recently, atraumatic, low-energy or insufficiency femoral shaft/subtrochanteric site fractures have been reported in patients on prolonged bisphosphonate therapy. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] These studies are evaluated in detail in Table 2 . Similar to our cases, some reports were of bilateral sequential femoral shaft fractures. [10, 11] Most of the alendronate-related fractures in literature reported differences from usual osteoporotic fractures, high-energy fractures and periprosthetic fractures, including: 1. Minor or no trauma 2. Alendronate use history for postmenopausal period 3. Prodromal (thigh) pain prior to fracture 4. Different localization from those commonly seen in osteoporotic fractures (spine, hip, wrist…etc.) 5. Bilaterality (sequential or simultaneous or impending) 6. Cortical hypertrophy or thickening at fracture site on radiographs 7. Unusual fracture pattern (transverse or short oblique; medial spike/beak) 8. Delayed fracture union time All 5 of our cases showed all the features mentioned above. These characteristics may be useful in the diagnosis of 'alendronate-related low-energy fractures'.
The subtrochanteric site of the femur is subjected to maximal bending forces and is known as its strongest region. [13, 18, 35] Low-energy stress fractures usually occur in athletes or military recruits. [36] Bilateral femoral fractures are also usually seen as pathological fractures or following high-energy trauma such as motor-vehicle accidents. Subtrochanteric fractures (especially bilateral) occurring after low-energy events are rare and are resultant of an underlying cause that weakens the bone. With inhibition of osteoclasts and impairment of the remodelization cycle, microarchitectural damage at the site of highest stress may occur. Gaeta et al. analyzed the CT scans of tibial stress fractures and found some resorption areas inside the typical cortical thickness site. [37] Our radiological findings on the contralateral impending fracture can be postulated to result from chronic suppression of bone remodeling by long-term bisphosphonate treatment with accumulation of old, highly-mineralized osteons and increased brittleness of bone (especially caused by increased Young's modulus). [38, 39] Bisphosphonates bind the bone tightly and the skeletal half-life of alendronate has been estimated at over 5 or 10 years. [4, 20, 24, [40] [41] [42] [43] Therefore, nonunion rates for such insufficiency fractures may be higher and union may be slower or incomplete even following the discontinuation of bisphosphonates. Weil et al. studied the surgical outcomes of bisphosphonate-related fractures and reported a much higher failure rate with intramedullary nailing which requires revision procedures. [44] In our cases, we also detected longer union time after surgical treatment and one patient required revision due to nonunion after 8 months (with additional autografting). We now believe that these bisphosphonate-related fractures must be thoroughly evaluated and treated using different and augmented approaches, such as autografting or recombinant bone morphogenetic proteins. Treatment modality should be chosen individually.
Questions and concerns for the long-term safety of bisphosphonates have arisen from reports of atypical femoral fractures, with studies reporting both increased or no increased risk available in the literature. [15, [45] [46] [47] [48] [49] [50] [51] [52] A meta-analysis based on database of three large randomized studies found that the occurrence of subtrochanteric or diaphyseal femur fracture (i.e. insufficiency fracture of the femur) was very rare, although there were insufficient numbers of events to reach defin- itive conclusions. [46] Several controlled epidemiological studies examining the association between bisphosphonate use and insufficiency fractures have also been published. Using a cohort created out of the Danish Hospital Discharge Registry and Prescription Database, Abrahamsen et al. found that high adherence to treatment was associated with a reduced insufficiency fracture risk, further suggesting that insufficiency fractures were caused by the extensive underlying osteoporosis instead of alendronate therapy. [45] Other studies have shown that atypical fractures have not increased. [47, 49] In contrast, a notable interconnection between long-term bisphosphonate use and insufficiency fractures has been reported by controlled observational studies. A Canadian report suggests that the long-term use (≥5 years) was associated with increased risk of insufficiency fracture of the femur (adjusted Odds ratio 2.74; 95% CI, 1.25-6.02). [50] This association was not present in shortterm users. Lenart et al. also reported significantly greater proportion of subtrochanteric or femoral shaft fractures in comparison to intertrochanteric or femoral neck fractures in patients who received long-term bisphosphonate therapy. [16] Another case-control study suggested that prolonged use of alendronate may cause suppression of bone remodeling and may be associated with insufficiency fractures of the femur. [13] We also believe that the long-term use (>5 years) of alendronate may be associated with its related fractures.
At the beginning of 2010, the FDA announced a report regarding bisphosphonate-related atypical fractures and reported no clear connection. However, the FDA also advised physicians to prescribe bisphosphonates according to guidelines and follow patients closely. [53] On the other hand, the Medicines and Healthcare products Regulatory Agency (MHRA), the drug regulatory agency in the UK, recommended the cessation of alendronate therapy in patients with atypical bisphosphonate-related fractures and the assessment of the benefits of alendronate treatment. [54] We believe that patients with atypical, bisphosphonate-related fractures should be individually reevaluated for risk factors with bone densitometry and biochemical bone turnover markers before making a decision on whether a drug holiday is necessary. The length of the drug holiday should be determined by close observation, bone mineral densitometry and biochemical bone turnover markers (urine cross-linked N-telopeptides of Type 1 collagen, cross-linked C-telopeptides of Type 1 collagen; bonespecific alkaline phosphatase, osteocalcin, pro-peptide of Type 1 collagen). [34, 55] Consultation with an endocrinologist may be helpful in the evaluation process and fracture risk assessment may be completed using the FRAX ® , WHO Fracture Risk Assessment Tool. [56] Teriparatide may be kept in mind for treatment continuation. [19] We did not perform any animal study or histomorphological assessment for patients. There was also no detection of biochemical bone turnover markers. These features were the limitations of our study. Continuous assessment of bone turnover markers and their relationship with bone mineral densitometry measures may be helpful to determine the actual status of bone metabolism occurring inside the body which in turn may assist in the decision to continue bisphosphonate use.
In conclusion, long-term (over 5 years) use of bisphosphonates may cause insufficiency fractures due to increased fragility and brittleness which have a close relationship with depressed bone remodeling. Although there is still no causal relationship between bisphosphonates and atypical, low-energy femoral shaft fractures, we have some concerns about the optimal usage time and long-term safety of bisphosphonate drugs.
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